Senior Director, Medchem Scale-Up
CurrentHead of Medchem Scale-Up Group since its inception in 2000.- Supervised 17 chemists (9 Ph.D., 5 M.S.; 3 B.S.)- Synthesized starting materials, intermediates, and preclinical tox lots for medicinal chemistry on multigram to kilogram scale.- Synthesized standards for various assays- Synthesized cold-labeled compounds- Performed kilo-scale enzymatic reactions- Proficient in flow chemistry. Used flow chemistry on kilo scale- Worked with several CROs in North America, Europe and Asia- Designed and updated an internal group website used to communicate with stakeholders- Experienced with DOE and reaction optimization- Member of the Chemistry Leadership Team (1997-2006, 2018-)- Recipient of the 2022 Grootenhuis Discovery Award (internal award given to a Vertexian who has displayed exemplary scientific leadership in the discovery of a breakthrough therapeutic candidate)- Recipient of a 2020 Platinum VOCAP (Vertex Outstanding Contributor Award Program) awarded for significant contributions above the core company values- Finalist for 2014 Vertex Outstanding Research AwardMedicinal Chemist (1996-2002)- Supervised 4 chemists (2 M.S., 2 B.S.)- Managed a lead generation team that synthesized hundreds of very potent and selective heterocyclic leads on several kinase programs including JNK3, GSK3, LCK, SYK, and JAK3.- Chemistry Head of the p38 2nd-generation program. - Designed and synthesized very potent and selective inhibitors of p38 - Designed synthetic routes for previously unknown substitution patterns on pyridine - Made presentations to external collaborators on the program. - Produced two clinical candidates that were substantially more potent and had much better physical properties than the 1st-generation inhibitors. - Filed several patents concerning the 1st-generation compounds and related scaffolds